Nuvation Bio CFO granted 748,130 stock options

Nuvation Bio Inc. reported that Chief Financial Officer Philippe Sauvage received a grant of stock options covering 748,130 shares on February 27, 2026.

Rhea-AI Filing Summary

Nuvation Bio Inc. reported that Chief Financial Officer Philippe Sauvage received a grant of stock options covering 748,130 shares on February 27, 2026. These options vest 25% on the one-year anniversary of February 27, 2026, then monthly over the following 36 months, subject to his continuous service.

Following this grant, Sauvage directly holds 12,673 shares of Class A common stock. This total includes 2,771 shares acquired on November 19, 2025 under the company’s 2021 Employee Stock Purchase Plan.

Insider Trade Summary

Grant/Award: 748,130 shares

Grant/Award 2 txns

Insider Sauvage Philippe

Role Chief Financial Officer

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	748,130	$0.00	$0.00
holding	Class A Common Stock	--	--	--

Holdings After Transaction: Stock Option (Right to Buy) — 748,130 contracts (Direct); Class A Common Stock — 12,673 shares (Direct)

Footnotes (2)

1. F1. Includes 2,771 shares acquired on November 19, 2025 under the 2021 Employee Stock Purchase Plan.
2. F2. Option vests as to 25% on the one year anniversary of 2/27/2026, and monthly thereafter over the following 36 months, subject to Reporting Person's continuous service on each such vesting date.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Nuvation Bio (NUVB) CFO Philippe Sauvage report?

Philippe Sauvage reported receiving a stock option grant for 748,130 shares on February 27, 2026. The options give him the right to buy Nuvation Bio Class A common stock, subject to a multi-year vesting schedule tied to continued service.

How do the new Nuvation Bio (NUVB) CFO options vest over time?

The 748,130 stock options vest 25% on the one-year anniversary of February 27, 2026. The remaining 75% then vest in equal monthly installments over the following 36 months, conditioned on Philippe Sauvage’s continuous service with Nuvation Bio.

How many Nuvation Bio (NUVB) shares does the CFO own after this Form 4?

After the reported transactions, CFO Philippe Sauvage directly holds 12,673 shares of Nuvation Bio Class A common stock. This figure reflects his current direct ownership as reported, separate from the newly granted but unexercised stock options.

What portion of Nuvation Bio (NUVB) CFO’s holdings came from the ESPP?

Out of Philippe Sauvage’s 12,673 directly held Nuvation Bio shares, 2,771 shares were acquired on November 19, 2025 under the 2021 Employee Stock Purchase Plan. This indicates prior participation in the company’s share purchase program for employees.

What type of security was granted to Nuvation Bio (NUVB) CFO on February 27, 2026?

The grant to CFO Philippe Sauvage was a stock option, described as a "Stock Option (Right to Buy)" Nuvation Bio Class A common stock. It is a derivative security, separate from his directly owned common shares reported in the same Form 4.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/03/2026 - 08:00 PM EST Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Sauvage Philippe

(Last) (First) (Middle)

C/O NUVATION BIO INC.

1500 BROADWAY, SUITE 1401

(Street)

NEW YORK NY 10036

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Nuvation Bio Inc. [ NUVB ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

3. Date of Earliest Transaction (Month/Day/Year)
02/27/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Class A Common Stock								12,673(1)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$5.91	02/27/2026		A		748,130		(2)	02/26/2036	Class A Common Stock	748,130	$0	748,130	D

Explanation of Responses:

1. Includes 2,771 shares acquired on November 19, 2025 under the 2021 Employee Stock Purchase Plan.

2. Option vests as to 25% on the one year anniversary of 2/27/2026, and monthly thereafter over the following 36 months, subject to Reporting Person's continuous service on each such vesting date.

	/s/ Stephen Dang, Attorney-in-Fact	03/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.